1. Introduction {#sec1}
===============

The wide application of *β*-blockers in coronary artery disease patients is partially supported by the general belief that they can reduce cardiac events. American guidelines recommend oral treatment with *β*-blockers during the hospital stay in acute coronary syndrome (ACS) patients without contraindications; the oral treatment should continue even after hospital discharge regardless of the presence of left ventricular (LV) dysfunction (class I, level of evidence B). However, European guidelines have a class IIa indication for patients with adequate LV function \[[@B1]--[@B5]\]. These recommendations are mainly drawn from studies conducted in the prereperfusion era \[[@B6]\] or studies of heart failure (HF) \[[@B7]\] patients. Besides, mixed results have been reported on the clinical benefit of *β*-blocker in patients without HF and ACS patients who have undergone percutaneous coronary intervention (PCI) \[[@B8]--[@B11]\]. In as much as the use of *β-*blocker reduced mortality before the reperfusion era, a recent meta-analysis in an ACS population revealed that it was no longer the case in the modern era \[[@B11]\]. Furthermore, studies showing that Asians are more susceptible to the adverse effects of *β*-blockers thereby offsetting its clinical benefits in the Asian population have been published \[[@B12]\]. There is scant data on *β*-blocker therapy among the Asian population who underwent PCI for ACS and had mild recessive or normal LV function.

In this study, we sought to examine the association between *β*-blocker therapy at discharge and long-term clinical outcomes in ACS patients who underwent PCI with adequate LV function, from a single center of China.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

We consecutively enrolled 10,724 patients treated with stent implantation in Fuwai Hospital for coronary artery disease, between January and December 2013, and obtained their baseline data from the medical records.

Patients with a diagnosis of ACS at admission and underwent PCI and those above 18 years formed the inclusion criteria. However, exclusion criteria included (1) patients with a history of heart failure (HF) or left ventricular ejection fraction (LVEF) \< 40%, (2) in-hospital death or unstable in the hospital, (3) patients missing *β*-blocker information, and (4) patients with contraindication to *β*-blocker therapy such as hypotension (systolic blood pressure \< 90 mmHg), significant bradycardia, or active asthma. Eventually, we included 5,631 patients in the study ([Figure 1](#fig1){ref-type="fig"}), and they were divided into two groups based on whether they used *β*-blockers at discharge or not.

We complied with the Declaration of Helsinki and obtained approval from the Institutional Review Board of Fuwai Hospital. In addition, all participants submitted written informed consent before the intervention.

2.2. Treatment and Intervention {#sec2.2}
-------------------------------

Coronary interventions were performed by experienced cardiologists according to standard guidelines \[[@B13]\], and the treatment strategy, i.e., PCI and stent type, was left to the discretion of the operators. Patients received a loading dose of aspirin (300 mg) and clopidogrel (300 mg) orally and continued the dual antiplatelet therapy (aspirin (100 mg/day) and clopidogrel (75 mg/day)) for at least 12 months. Although unfractionated heparin (100 U/kg) was applied in all patients for anticoagulation during the procedure, glycoprotein IIb/IIIa antagonists were also administrated on a necessity basis. Standard secondary prevention for CAD was prescribed according to established guidelines \[[@B14]\].

2.3. Definitions and Outcomes {#sec2.3}
-----------------------------

The follow-up was prespecified to occur after 1, 6, 12, and 24 months. The primary outcome was all-cause death, defined as all incident death that could be attributed to a cardiac or noncardiac etiology, while secondary outcomes included cardiac death, recurrent MI, and major adverse cardiovascular and cerebrovascular events (MACCE). Death that could not be attributed to a noncardiac etiology was considered a cardiac death. MI was defined by the third universal definition of myocardial infarction \[[@B15]\], while MACCE was defined as the composite of all-cause death, nonfatal MI, unplanned target vessel revascularization, stent thrombosis, and stroke during the follow-up. Unplanned target vessel revascularization was defined as repeat percutaneous intervention or surgical bypass of any segment of the target vessel for ischemic symptoms and event-driven. Stent thrombosis was defined according to the Academic Research Consortium, including definite and probable in the analysis.

All endpoints were adjudicated centrally by 2 independent cardiologists, and disagreement was resolved by consensus.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Continuous variables are presented as the mean ± SD or median (25th and 75th percentiles) when appropriate and were compared by Student\'s *t*-test or the Mann-Whitney *U* test. Categorical variables are presented as frequency (percentage) and were compared using the *chi-squared* test or Fisher\'s exact test. Survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. To estimate the hazard ratio (HR) and the 95% confidence interval (CI) of *β*-blocker therapy and adverse event risk, we performed Cox proportional regression analysis. Variables with a *P* value \< 0.05 in the univariate Cox proportional hazard model were included for further multivariate analysis (details in [Table 1](#tab1){ref-type="table"}). Subgroup analysis was conducted with the covariates of clinical presentation (AMI *vs.* unstable angina (UA)). Additionally, we conducted the landmark analysis to assess outcomes at 1 year and between 1 and 2 years in overall and subgroups.

Significance was set at *P* \< 0.05, and all analyses were performed using *SPSS 22.0* (IBM Corp., USA).

3. Results {#sec3}
==========

3.1. Baseline and Procedure Characteristics {#sec3.1}
-------------------------------------------

Out of the 5,631 patients discharged alive with LVEF ≥ 40% and without HF, 5,043 (89.56%) received *β*-blocker treatment at discharge. The baseline characteristics of patients are presented in [Table 2](#tab2){ref-type="table"}. In particular, patients with *β*-blocker treatment at discharge were mainly younger, females, and nonsmokers. In addition, a larger proportion of those discharged with *β*-blocker had diabetes and dyslipidemia, presenting with AMI. Patients with *β*-blocker therapy at discharge had more complicated lesions and a higher SYNTAX score (SS). However, they recorded significantly lower residual SS (rSS) after the intervention, compared with those without *β*-blockers at discharge.

3.2. Two-Year Clinical Outcomes in the Overall Population {#sec3.2}
---------------------------------------------------------

5,603 (99.5%) patients had complete two-year follow-up information as summarized in [Table 3](#tab3){ref-type="table"}. [Table 1](#tab1){ref-type="table"} presents the landmark analysis of events occurring within and after 1 year, while Kaplan-Meier curves of the overall population for time to all-cause death, cardiac death, MI, and MACCE are shown in [Figure 2](#fig2){ref-type="fig"}. At the 2-year follow-up, the incidences of all-cause death (HR 0.69, 95% CI 0.32 to 1.47, *P* = 0.336), cardiac death (*P* = 0.925), MI (*P* = 0.338), or MACCE (*P* = 0.614) did not differ significantly between the two groups. Multivariate Cox proportional regression analysis revealed that age was an independent risk factor, while clopidogrel use was a protective factor for 2-year all-cause death. Moreover, age, prior PCI, and rSS \> 8 were independent risk factors for 2-year cardiac death, while LVEF was a protective factor. Prior coronary artery bypass grafting and rSS \> 8 were however independent risk factors for 2-year nonfatal MI. Additionally, left ascending artery lesion, GPIIb/IIIa use, and rSS \> 8 were independent risk factors for 2-year MACCE. Rates of clinical outcomes within and after 1 year were similar between the two groups as revealed by the landmark analysis.

3.3. Subgroup Analysis {#sec3.3}
----------------------

[Table 2](#tab2){ref-type="table"} shows the baseline and procedure characteristics of subgroups, while Tables [1](#tab1){ref-type="table"} and [3](#tab3){ref-type="table"} summarize the 2-year clinical outcomes and landmark analyses. Patients discharged with *β*-blocker and manifesting unstable angina (UA) recorded significantly lower 2-year mortality compared with those discharged without *β*-blocker (HR 0.42, 95% CI 0.19-0.94, *P* = 0.034). Together with *β*-blocker use, clopidogrel use served as a protective factor for all-cause death. Besides, landmark analysis showed that the use of a *β*-blocker was effective on all-cause death after the first year of follow-up ([Figure 3](#fig3){ref-type="fig"}). However, the risk of all-cause death beyond 1 year was similar between the two groups. Although not statistically significant (HR 0.36, 95% CI 0.10-1.32, *P* = 0.123), we observed a decline in 2-year cardiac deaths among patients discharged with *β*-blockers. Landmark analysis also revealed a protective effect of *β*-blocker use on 1-year cardiac death, but not beyond 1 year ([Table 1](#tab1){ref-type="table"}). There was no impact of *β*-blocker use at discharge on 2-year MI or MACCE. In the UA subpopulation, clopidogrel use was a protective factor for 2-year cardiac death. In addition, the prior coronary artery bypass graft and rSS \> 8 were independent risk factors for 2-year nonfatal MI, while left ascending artery lesion and rSS \> 8 were independent risk factors for 2-year MACCE.

In the AMI subpopulation, we did not observe any association of *β*-blocker use at discharge, with clinical outcomes, shown either within or after a 1-year follow-up. However, in patients with AMI, stroke and left main lesion were significantly related to 2-year all-cause death; hence, we considered prior MI and left main lesion to be independent risk factors for 2-year cardiac death. Peripheral vascular disease, left main lesion, and rSS \> 8 were independent risk factors for 2-year nonfatal MI, while left ascending artery lesion and rSS \> 8 were independent risk factors for 2-year MACCE.

4. Discussion {#sec4}
=============

In the present study, we investigated the association of *β*-blocker therapy with clinical outcomes in real-life patients using data from a large, prospective, single-center series in China. Moreover, among ACS patients who underwent PCI with normal or mildly reduced LVEF, the use of *β*-blockers at discharge did not correlate with a lower risk of clinical outcomes up to 2 years. However, in the subgroup analysis of the UA population, a reduction of mortality with *β*-blocker therapy at discharge was observed, though the superiority was only significant within the first year, but not after a 2-year follow-up.

*β*-Blockers are accepted as the standard care for coronary heart disease, especially in MI patients. As mentioned before, there is a divergence between international guidelines in their recommendations for the use of *β*-blockers in ACS patients without HF, or LV dysfunction \[[@B1]--[@B4], [@B16]\]. Besides, all the recommendations relying on evidence from the prerevascularization era \[[@B6]\] and expert opinion (level C) only in patients with normal LV function with NSTE-ACS \[[@B7]\]. Despite its benefits on hard clinical outcomes in ACS patients with HF and reduced LV function being evident in the pre- and revascularization eras \[[@B9]\], the use of *β*-blockers remains controversial in patients undergoing PCI with adequate LV function \[[@B9], [@B17], [@B18]\]. Studies on the Asian population have reported inconsistent results \[[@B8], [@B19]--[@B21]\], with scant data focused on the relatively low-risk patients with normal or mild recessive LVEF. In Li et al.\'s Chinese population data, *β*-blocker use significantly lowered the risk of all-cause death in ACS patients who underwent PCI. However, the relatively low-risk population without HF or LV dysfunction was not explored \[[@B19]\]. In Nakatani et al.\'s analysis in Japanese, *β*-blocker therapy at discharge had beneficial effects for high-risk patients only \[[@B21]\].

This study, therefore, sought to clarify this controversy. After full adjustment of potential confounding factors, we demonstrated that *β*-blocker therapy at discharge was associated with a significant reduction in 2-year mortality in patients who underwent PCI for UA and had adequate LVEF. Landmark analysis demonstrated the benefit of *β*-blocker use on all-cause death and cardiac death at a 1-year follow-up, but not beyond that period. Since we were uncertain of the duration of *β*-blocker use after discharge, our results should be interpreted with some caution.

In the era of PCI and modern medical therapy, it is true that the clinical outcomes of relatively low-risk patients, with normal or mild recessive LV function after ACS, would be improved. However, recurrent myocardial ischemia, tachyarrhythmia, and adrenergic activation remain serious problems for these patients. Since there is no other optimal substitute for *β*-blockers in controlling these problems effectively \[[@B22]\], our results supported the *β*-blocker use in relatively low-risk patients who underwent PCI for UA and had adequate LVEF.

Patients with myocardial damage from AMI may have higher levels of sympathetic tone and circulating catecholamine than those with UA, hence more likely to benefit from *β*-blocker therapy. However, in the present study, we did not observe any significant impact of *β*-blocker use on clinical outcomes in the AMI population. This could be attributed to the sample size and relatively low event rates encountered in the AMI subpopulation. It is therefore not accurate to conclude from this study alone that the drug is ineffective in patients with AMI.

Beyond the medicine, the present study also revealed the importance of interventional therapy for the prognosis of the ACS population. Besides, incomplete revascularization (rSS \> 8) was shown to be an independent risk factor for MI and MACCE. This was true for the overall AMI and UA populations, respectively.

This study, however, has the following limitations. First, it is an observational study; hence, conventional limitations for such apply. Secondly, the present study was conducted in a Chinese population with relatively low incidences of cardiac events. Despite the total population of 5,631 cases, only 588 of the patients did not use *β*-blockers, which is a small sample size. Thirdly, unmeasured confounders may have led to biased results. Finally, the study lacks data on specific *β*-blockers and doses, and as mentioned before, we are uncertain of the duration that *β*-blockers were administered after discharge. Large-scale, prospective, randomized controlled trials should be conducted to clarify the effects of long-term *β*-blocker therapy in ACS patients who have undergone PCI with adequate LVEF.

5. Conclusion {#sec5}
=============

Our findings are in agreement that *β-*blocker significantly lowers the rate of all-cause death up to 1 year, in UA patients who have undergone PCI and have adequate LVEF. Its role in patients with AMI also deserves further exploration.
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![Flow diagram describing the study population. ACS: acute coronary syndrome; CAD: coronary artery disease; HF: heart failure; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention.](CDTP2020-4351469.001){#fig1}

![Kaplan-Meier curve for all-cause death (a), cardiac death (b), myocardial infarction (c), and MACCE (d) in the overall population. MACCE: major adverse cardiovascular and cerebrovascular events.](CDTP2020-4351469.002){#fig2}

![All-cause death in patients with unstable angina: (a) incidence of all-cause death in two groups; (b) landmark analysis discriminating between death occurring before and after 1-year follow-up.](CDTP2020-4351469.003){#fig3}

###### 

Landmark analyses in 2-year clinical outcomes.

                       Overall population   AMI subpopulation   UA subpopulation                                                                                                             
  -------------------- -------------------- ------------------- ------------------- ------- ------------ ----------- ------------------- ------- ------------ ----------- ------------------ -------
  0-2 years                                                                                                                                                                                  
   Death               47 (0.9)             8 (1.4)             0.69 (0.32-1.47)    0.336   16 (1.1)     0 (0.0)     NA                  NA      31 (0.9)     8 (1.7)     0.42 (0.19-0.94)   0.034
   Cardiac death       24 (0.5)             3 (0.5)             0.94 (028-3.18)     0.925   10 (0.7)     0 (0.0)     NA                  NA      14 (0.4)     3 (0.6)     0.36 (0.10-1.32)   0.123
   MI                  29 (0.6)             5 (0.9)             0.63 (0.24-1.63)    0.338   8 (0.6)      2 (1.7)     0.32 (0.07-1.54)    0.156   21 (0.6)     3 (0.6)     0.84 (0.25-2.81)   0.772
   MACCE               538 (10.7)           61 (10.4)           0.93 (0.72-1.22)    0.614   155 (10.7)   12 (10.3)   1.02 (0.57-1.85)    0.935   383 (10.6)   49 (10.4)   0.91 (0.67-1.22)   0.517
  0-1 year                                                                                                                                                                                   
   Death               17 (0.3)             4 (0.7)             0.55 (0.18-1.73)    0.316   10 (0.7)     0 (0.0)     NA                  NA      7 (0.2)      4 (0.8)     0.17 (0.04-0.65)   0.010
   Cardiac death       7 (0.1)              2 (0.3)             0.61 (0.11-3.26)    0.562   5 (0.3)      0 (0.0)     NA                  NA      2 (0.1)      2 (0.4)     0.12 (0.01-0.99)   0.049
   MI                  14 (0.3)             4 (0.7)             0.40 (0.13-1.22)    0.106   3 (0.2)      1 (0.9)     0.32 (0.03-3.07)    0.322   11 (0.3)     3 (0.6)     0.69 (0.15-3.14)   0.633
   MACCE               354 (7.0)            39 (6.6)            0.94 (0.68-1.32)    0.749   107 (7.4)    11 (9.5)    0.77 (0.41-1.44)    0.409   247 (6.9)    28 (5.9)    1.01 (0.68-1.50)   0.954
  *\>*1 year-2 years                                                                                                                                                                         
   Death               30 (0.6)             4 (0.7)             0.80 (0.28-2.30)    0.677   6 (0.4)      0 (0.0)     NA                  NA      24 (0.67)    4 (0.85)    0.66 (0.22-1.95)   0.455
   Cardiac death       17 (0.3)             1 (0.2)             1.68 (0.22-12.80)   0.614   5 (0.3)      0 (0.0)     NA                  NA      12 (0.3)     1 (0.2)     0.84 (0.11-6.80)   0.874
   MI                  15 (0.3)             1 (0.2)             1.56 (0.21-11.80)   0.669   5 (0.4)      1 (0.9)     0.35 (0.04-3.03)    0.341   10 (0.28)    0 (0.00)    NA                 NA
   MACCE               184 (3.9)            22 (4.0)            0.91 (0.58-1.42)    0.684   48 (3.6)     1 (1.0)     3.88 (0.53-28.16)   0.181   136 (4.1)    21 (4.7)    0.76 (0.48-1.21)   0.253

Values are presented as *n* (%). Variables with a *P* value \< 0.05 in the univariate Cox proportional hazard model were included. In the overall population, for all-cause death, the variables, namely, age, stroke, COPD, prior PCI, CCr \< 60 mL/min, LVEF, heart rate, rSS, and clopidogrel use, were adjusted. For cardiac death, the variables, namely, age, prior MI, prior PCI, prior CABG, CCr \< 60 mL/min, LVEF, heart rate, rSS, and clopidogrel use, were adjusted. for MI, the variables, namely, CCr \< 60 mL/min, prior CABG, and rSS, were adjusted. For MACCE, the variables, namely, diabetes, stroke, prior MI, prior CABG, LVEF, rSS, LAD lesion, and GPIIb/IIIa inhibitor use, were adjusted. In the UA subpopulation, variables of age, COPD, LVEF, and clopidogrel use were adjusted for all-cause death; age, COPD, prior coronary artery bypass graft, LVEF, heart rate, rSS, IABP use, and clopidogrel use were adjusted for cardiac death; variables of prior CABG, LVEF, and rSS were adjusted for MI; variables of diabetes, stroke, prior MI, prior CABG, SS, rSS, LAD lesion, IABP use, and GPIIb/IIIa inhibitor use were adjusted for MACCE. In the AMI subpopulation, variables of age, sex, stroke, prior PCI, current smoking, CCr \< 60 mL/min, and left main lesion were adjusted for all-cause death; variables of age, prior MI, prior PCI, PAD, left main lesion, CCr \< 60 mL/min, and rSS were adjusted for cardiac death; variables of PAD, left main lesion, and rSS were adjusted for MI; variables of LAD lesion, rSS, and GPIIb/IIIa inhibitor use were adjusted for MACCE. CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; CI: confidence interval; HR: hazard ratio; IABP: intra-aortic balloon counterpulsation; LAD: left anterior descending artery; LVEF: left ventricular ejection function; MACCE: major adverse cardiovascular and cerebrovascular events; MI: myocardial infarction; PAD: peripheral vascular disease.

###### 

Baseline characteristics of patients.

                                  Overall population   AMI subpopulation   UA subpopulation                                                                                                   
  ------------------------------- -------------------- ------------------- ------------------ ------------------- ------------------- --------- ---------------------- ---------------------- ---------
  Clinical characteristics (%)                                                                                                                                                                
   Age (years)                    58.0 (50.0, 65.0)    59.0 (53.0, 67.0)   0.027              58.0 (50.0, 67.0)   56.0 (48.0, 63.0)   0.009     59.0 (52.0, 66.0)      59.0 (53.0, 67.0)      0.687
   Male                           3,844 (76.2)         473 (80.4)          0.022              1,220 (84.5)        100 (86.2)          0.621     2,624 (72.9)           373 (79.0)             0.005
   BMI (kg/m^2^)                  26.0 (23.9, 27.8)    25.4 (23.5, 27.3)   \<0.001            26.0 (23.9, 27.8)   25.6 (23.2, 27.1)   0.200     25.9 (23.8, 27.8)      25.3 (23.5, 27.3)      0.002
   Diabetes                       1,499 (29.7)         127 (21.6)          \<0.001            388 (26.9)          21 (18.1)           0.039     1,111 (30.3)           106 (22.5)             \<0.001
   Hypertension                   3,226 (64.0)         356 (60.5)          0.102              832 (57.6)          65 (56.0)           0.740     2,394 (66.5)           291 (61.7)             0.036
   Dyslipidemia                   3,380 (67.0)         357 (60.7)          0.002              892 (61.8)          60 (51.7)           0.033     2,488 (69.1)           297 (62.9)             0.006
   Prior MI                       639 (12.7)           72 (12.2)           0.768              92 (6.4)            9 (7.8)             0.559     547 (15.2)             63 (13.3)              0.289
   Prior PCI                      1,014 (20.1)         125 (21.3)          0.511              247 (17.1)          29 (25.0)           0.032     767 (21.3)             96 (20.3)              0.627
   Prior CABG                     198 (3.9)            17 (2.9)            0.215              31 (2.1)            2 (1.7)             1.000     167 (4.6)              15 (3.2)               0.148
   Stroke                         531 (10.5)           61 (10.4)           0.908              125 (8.7)           15 (12.9)           0.121     406 (11.3)             46 (9.7)               0.318
   PAD                            104 (2.1)            14 (2.4)            0.61               19 (1.3)            3 (2.6)             0.221     85 (2.4)               11 (2.3)               0.966
   COPD                           112 (2.2)            21 (3.6)            0.041              33 (2.3)            4 (3.4)             0.349     79 (2.2)               17 (3.6)               0.058
   Current smoking                2,896 (57.4)         373 (63.4)          0.005              942 (65.2)          91 (78.4)           0.004     1954 (54.3)            282 (59.7)             0.025
  Presenting characteristics                                                                                                                                                                  
   SBP (mmHg)                     125 (116, 140)       125 (117, 140)      0.978              120 (110, 130)      120 (105, 130)      0.119     130.0 (120.0, 140.0)   129.0 (120.0, 140.0)   0.892
   Heart rate (bpm)               70 (63, 76)          62 (57, 70)         \<0.001            70.0 (64.0, 78.0)   61.5 (56.0, 73.8)   \<0.001   69.0 (63.0, 76.0)      62.0 (57.0, 69.0)      \<0.001
   CCr \< 60 mL/min (%)           1,939 (38.4)         237 (40.3)          0.382              521 (36.5)          51 (44.0)           0.109     1,412 (39.2)           186 (39.4)             0.942
   CK-MB (U/L)                    12.0 (9.0, 16.0)     12.0 (9.0, 15.0)    0.209              12.0 (9.0, 17.0)    12.0 (8.0, 15.5)    0.146     11.0 (9.0, 15.0)       12.0 (9.0, 15.0)       0.796
   LVEF                           63.0 (60.0, 67.0)    64.6 (60.0, 68.0)   0.002              60.0 (55.0, 64.0)   60.0 (55.0, 65.0)   0.659     65.0 (60.2, 68.0)      65.0 (61.0, 68.3)      0.135
    40-49%                        217 (4.3)            16 (2.7)            0.068              125 (8.7)           10 (8.6)            0.989     92 (2.6)               6 (1.3)                0.087
  Procedure characteristics (%)                                                                                                                                                               
   SYNTAX score                   10 (6, 16)           8 (5, 14)           \<0.001            11.0 (7.0, 17.5)    12.0 (7.0, 18.4)    0.435     9.5 (5.0, 16.0)        7.0 (4.3, 12.4)        \<0.001
   Residual SYNTAX score                                                   0.001                                                      0.178                                                   0.001
    0                             2,576 (52.7)         350 (60.8)                             752 (52.7)          66 (57.4)                     1,824 (52.7)           284 (61.6)             
    0-8                           1,622 (33.2)         157 (27.3)                             463 (32.4)          28 (24.3)                     1,159 (33.5)           129 (28.0)             
    \>8                           688 (14.1)           69 (12.0)                              212 (14.9)          21 (18.3)                     476 (13.8)             48 (10.4)              
   Left main lesion               122 (2.4)            7 (1.2)             0.058              25 (1.7)            3 (2.6)             0.459     97 (2.7)               4 (0.8)                0.015
   LAD                            4,588 (91.0)         537 (91.3)          0.779              1,309 (90.7)        103 (88.7)          0.511     3,279 (91.1)           434 (91.9)             0.544
   IABP use                       49 (1.0)             4 (0.7)             0.489              27 (1.9)            3 (2.6)             0.485     22 (0.6)               1 (0.2)                0.508
   IVUS use                       276 (5.5)            21 (3.6)            0.051              53 (3.7)            2 (1.7)             0.274     223 (6.2)              19 (4.0)               0.061
   GPIIb/IIIa inhibitor use       792 (15.7)           85 (14.5)           0.429              256 (17.7)          21 (18.1)           0.919     536 (14.9)             64 (13.6)              0.442
  Medication at discharge                                                                                                                                                                     
   Aspirin                        4,993 (99.0)         568 (96.6)          \<0.001            1,437 (99.5)        105 (90.5)          \<0.001   3,556 (98.8)           463 (98.1)             0.195
   Clopidogrel                    4,963 (98.4)         573 (97.4)          0.086              1,427 (98.8)        109 (94.0)          \<0.001   3,536 (98.6)           464 (98.3)             0.931
   Statin                         4,871 (96.6)         547 (93.0)          \<0.001            1,395 (96.6)        96 (82.8)           \<0.001   3,476 (96.6)           451 (95.6)             0.254
   ACEI/ARB                       2,742 (54.4)         272 (46.3)          \<0.001            1,051 (72.8)        71 (61.2)           0.008     1,691 (47.0)           201 (42.6)             0.071
   CCB                            2,547 (50.5)         314 (53.4)          0.184              406 (28.1)          33 (28.4)           0.939     2,141 (59.5)           281 (59.5)             0.985

Values are presented as *n* (%), mean ± SD, or median (IQR). ACEI: angiotensin-converting enzyme inhibitors; AMI: acute myocardial infarction; ARB: angiotensin II receptor antagonists; BMI: body mass index; CABG: coronary artery bypass graft; CCB: calcium channel blockers; CCr: creatinine clearance; CK-MB: creatine kinase-MB; COPD: chronic obstructive pulmonary disease; IABP: intra-aortic balloon counterpulsation; IVUS: intravascular ultrasound; LAD: left anterior descending artery; LVEF: left ventricular ejection fraction; PAD: peripheral vascular disease; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; UA: unstable angina.

###### 

2-year clinical outcomes of the patients.

                  Overall population   AMI subpopulation   UA subpopulation                                                             
  --------------- -------------------- ------------------- ------------------ ------------ ----------- ------- ------------ ----------- -------
  Death           47 (0.9)             8 (1.4)             0.317              16 (1.1)     0 (0.0)     0.625   31 (0.9)     8 (1.7)     0.106
  Cardiac death   24 (0.5)             3 (0.5)             0.909              10 (0.7)     0 (0.0)     1.000   14 (0.4)     3 (0.6)     0.437
  MI              29 (0.6)             5 (0.9)             0.395              8 (0.6)      2 (1.7)     0.167   21 (0.6)     3 (0.6)     0.889
  TVR             421 (8.3)            47 (8.0)            0.768              126 (8.7)    9 (7.8)     0.722   295 (8.2)    38 (8.1)    0.913
  ST              30 (0.6)             2 (0.3)             0.437              9 (0.6)      0 (0.0)     1.000   21 (0.6)     2 (0.4)     1.000
  Stroke          71 (1.4)             8 (1.4)             0.926              14 (1.0)     2 (1.7)     0.336   57 (1.6)     6 (1.3)     0.842
  MACCE           538 (10.7)           61 (10.4)           0.827              155 (10.7)   12 (10.3)   1.000   383 (10.6)   49 (10.4)   0.937

Values are presented as *n* (%). ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular events; MI: myocardial infarction; TVR: unplanned target vessel revascularization.

[^1]: Academic Editor: Leonardo De Luca
